Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interleukin-2 and Sargramostim in Metastatic Melanoma
NCT00085579Phase 2Withdrawn
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2004
- Primary completion
- Mar 2005
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin, sargramostim in melanoma, sponsored by Memorial Sloan Kettering Cancer Center. Planned start Mar 2004; status: withdrawn.
02
Drugs
aldesleukinsargramostim
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00085579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085579.